Deepak Srivastava

Deepak Srivastava is the current Director at Tenaya Therapeutics. Prior to this, they served as the Chief Business Officer at REGENXBIO Inc. from February 2016 to January 2018. Deepak has also been a part of the Massachusetts Institute of Technology as a committee member for their NEWDIGS consortium - Financing of Cures in the US (FoCUS) project from January 2016 to December 2018. From January 2014 to December 2016, Deepak served as the Chair for the Reimbursement Committee at Alliance for Regenerative Medicine. Deepak was also the Vice President for Global Commercial Development and External Affairs at bluebird bio from May 2011 to February 2016. Other companies Deepak has worked for include Third Rock Ventures, Sanofi Genzyme, and Genzyme.

Deepak Srivastava received their MBA from Harvard Business School and their BS in Electrical Engineering from Stanford University.